Institut d'Investigacions Biomèdiques August Pi i Sunyer-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2023

  1. IGLV3-21R110 mutation has prognostic value in patients with treatment-naive chronic lymphocytic leukemia

    Blood Advances

2020

  1. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 38, Núm. 8, pp. 784-792

  2. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients

    Blood Cancer Journal, Vol. 10, Núm. 2

2019

  1. Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population

    British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491

2018

  1. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia

    Leukemia and Lymphoma, Vol. 59, Núm. 10, pp. 2318-2326

2016

  1. High-resolution copy number analysis of paired normal-tumor samples from diffuse large B cell lymphoma

    Annals of Hematology, Vol. 95, Núm. 2, pp. 253-262

2015

  1. Detection of chromothripsis-like patterns with a custom array platform for chronic lymphocytic leukemia

    Genes Chromosomes and Cancer, Vol. 54, Núm. 11, pp. 668-680

  2. Non-coding recurrent mutations in chronic lymphocytic leukaemia

    Nature, Vol. 526, Núm. 7574, pp. 519-524

  3. Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential

    Leukemia, Vol. 29, Núm. 5, pp. 1186-1194

2014

  1. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption

    Haematologica

  2. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

    Blood, Vol. 123, Núm. 24, pp. 3790-3796

  3. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

    Blood, Vol. 123, Núm. 20, pp. 3073-3079

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

  2. Evaluating gene expression profiling by quantitative polymerase chain reaction to develop a clinically feasible test for outcome prediction in multiple myeloma

    British Journal of Haematology, Vol. 163, Núm. 2, pp. 223-234

  3. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome

    Leukemia, Vol. 27, Núm. 5, pp. 1100-1106

2012

  1. Chronic lymphocytic leukaemia with 17p deletion: A retrospective analysis of prognostic factors and therapy results

    British Journal of Haematology, Vol. 157, Núm. 1, pp. 67-74

  2. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia

    Nature Genetics, Vol. 44, Núm. 1, pp. 47-52

  3. SNP-based mapping arrays reveal high genomic complexity in monoclonal gammopathies, from MGUS to myeloma status

    Leukemia, Vol. 26, Núm. 12, pp. 2521-2529

2011

  1. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

    Nature, Vol. 475, Núm. 7354, pp. 101-105

2010

  1. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: A randomised trial

    The Lancet Oncology, Vol. 11, Núm. 10, pp. 934-941